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ABSTRACT
Virtually all human cancers display chromosome instability (CIN), a condition 
in which chromosomes are gained or lost at a high rate. CIN occurs early in cancer 
development where it may undermine the advance of the neoplastic disease. With 
the aim of establishing the mechanisms underlying CIN in cancer, we investigated 
possible links between telomere-dysfunction and centrosome defects, which were 
seen to coincide in early in breast carcinogenesis using human mammary epithelial 
cells (HMECs). In this study, we show that TP53 proficient vHMECs cells develop 
centrosome aberrations when telomere-dysfunction genotoxic stress is produced in 
the presence of a defective p16INK4a setting and in parallel with an activation of the 
DNA damage checkpoint response. These aberrations consist of the accumulation 
of centrosomes in polyploid vHMECs, plus centriole overduplication in both diploid 
and polyploid cells, thus reflecting that distinct mechanisms underlie the generation 
of centrosome aberrations in vHMECs. Transduction of vHMEC with hTERT, which 
rescued the telomere dysfunction phenotype and consequently reduced DNA damage 
checkpoint activation, led to a progressive reduction of centrosome aberrations with 
cell culture, both in diploid and in polyploid vHMECs. Radiation-induced DNA damage 
also raised centrosome aberrations in vHMEC-hTERT. Collectively, our results, using 
vHMECs define a model where p16INK4a deficiency along with short dysfunctional 
telomeres cooperatively engenders centrosome abnormalities before p53 function 
is compromised.
INTRODUCTION
Chromosomal instability (CIN) is a hallmark of 
almost all human cancer cells, and reflects ongoing 
changes of chromosome structure and number over time. 
CIN most likely occurs early in the development of cancer, 
and may represent an important step in promoting the 
multiple genetic changes required for the initiation and/
or progression of the disease. By constantly reshuffling 
the cell karyotype, CIN is thought to confer a selective 
advantage on subclones of cells, enabling their outgrowth 
and eventual dominance in a local tissue environment. To 
date, however, the specific molecular mechanisms that 
underlie CIN in cancer cells still remain obscure.
Centrosomes function as microtubule-organizing 
centers of animal cells that build up the mitotic spindle 
during cell division. Therefore, the acquisition of extra 
centrosomes in a cell can arrange aberrant spindles that, 
through the formation of merotelic attachments, may lead 
to the onset of CIN [1-3]. Emerging data are demonstrating 
the detection of centrosome defects in several pre-
neoplasia lesions, but not in normal tissue (reviewed by 
[4]), hence, it has been hypothesized that centrosome 
amplification might lead to the malignant transformation 
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of cells. Centrosome defects in human cancer cells consist 
of structural changes in shape, size, number, and position, 
as well as functional defects. Potential mechanisms for 
the generation of centrosome aberrations in cancer cells 
include alterations in proteins controlling the centrosome 
duplication cycle, which could initiate multiple cycles 
of centriole replication -overduplication -within a single 
cell cycle [5]; or accumulation of extra centrosomes when 
cell division does not occur because of mitotic slippage, 
endoreduplication, aborted cytokinesis or cell fusion [6, 
7]. Another possible scenario for increasing numbers of 
centrosomes involves de novo formation of centrioles 
during interphase [8]. Although these fundamental 
processes are not mutually exclusive and could be acting 
at the same time or in a sequential fashion, the precise 
mechanisms driving centrosome aberrations early in 
cancer development are still undefined. Another possible 
cause for the onset of CIN in sporadic cancers is telomere 
dysfunction. When telomeres become dysfunctional, they 
set breakage-fusion-bridge (BFB) cycles in motion that 
are capable of producing high levels of CIN, generating 
both structural and numerical chromosome aberrations, as 
well as changes in cell ploidy [9, 10]. Very short telomeres 
have also been reported to be an early alteration in many 
human cancers [11, 12]. And compelling evidence, in 
mouse models, supports the notion that loss of telomere 
repeats contributes to carcinogenesis [13].
In breast cancer, there is evidence for the presence 
of centrosome aberrations -before TP53 mutations are 
attained [14-16] -and high levels of end-to-end fusions [17] 
as early events in carcinogenesis. The aim of this study 
was to investigate whether there is a functional explanation 
for the coincident detection of telomere dysfunction and 
centrosome defects early in breast cancer development. 
For this reason, we used the human mammary epithelial 
cell model (HMEC), which mimics in vitro the genomic 
events driving malignant progression in the breast [18, 
19]. When HMECs are grown in culture under standard 
conditions, they experience a growth plateau from which 
some cells can escape, proliferate, expand and display 
progressive telomere dysfunction due to CDKN2A 
promoter hypermethylation [20]. Considering that cells 
with p16INK4a deficiencies develop centrosome aberrations 
when a transient inhibition of DNA synthesis occurs [21], 
we hypothesized that a similar phenotype could arise due 
to the genotoxic damage driven by telomere dysfunction. 
Accordingly, our study demonstrates the accumulation of 
centrosome aberrations, concomitant to the intensification 
of the telomere-dysfunction phenotype, and in parallel 
with an activation of the DNA damage checkpoint 
response in vHMECs. Moreover, transduction of vHMEC 
with hTERT, which rescues the telomere dysfunction 
phenotype and consequently reduced DNA damage 
checkpoint activation, rendered a progressive reduction of 
centrosome aberrations with cell culture. Noteworthy, in 
contrast to the centriole pair splitting events reported [21] 
the main centrosomal aberration in telomere compromised 
p16INK4a -deficient vHMECs was the presence of centriole 
overduplication. We show that the loss of p16INK4a function 
in vHMEC alone is not sufficient to cause centrosome 
amplification, but rather creates the permissive conditions 
for their development in response to the genotoxic stress 
of telomere dysfunction. 
RESULTS
Tetraploid populations increase in telomere-
deficient vHMECs
For the evaluation of ploidy levels in post-stasis 
vHMEC lines (830 and 440212) throughout the cell 
culture, a combination of β-tubulin immunofluorescence 
with fluorescent in situ hybridization (FISH) was 
performed. This immunoFISH protocol enabled the 
different nucleus inside the same cytoplasm to be 
visualized, allowing the ploidy of mononucleated (MN) 
and binucleated (BN) cells to be easily recorded. vHMEC 
were analyzed at an early culture stage (PD19 and PD21, 
for 830 and 440212, respectively) just after a period of 
selection when clones with p16INK4a inactivation (Figure 
S1A) acquire proliferation capacity due to promoter 
hypermethylation [20, 22]. In addition, late culture stages 
(PD34, for both cell donors) were analyzed to detect any 
abnormalities gained over time. These specific vHMEC 
lines have a limited potential and cease proliferation 
-agonescence -at around PD35.
A total of 1566 cells (554 for 830, and 1012 for 
440212), grown in chamberslides, were evaluated for 
ploidy levels using two different centromere-specific 
probes. At early PD, a small fraction of cells was confirmed 
to be polyploid in both donors. Importantly, however, 
there was a significant increase in polyploidy with PDs 
for both cell lines (10.66% vs 32.27% in 830, X2, p < 0.05; 
and 6.44% vs 25.26% in 440212, X2, p < 0.05) (Figure 
1A). These results are in accordance with the already 
defined tetraploidization effect of telomere dysfunction 
[9, 23]. Indeed, signatures of telomere dysfunction such 
as telomere-signal free ends, chromosome end-to-end 
fusions without detectable telomeric DNA and/or anaphase 
bridges were observed to increase with PDs in both cell 
lines (Figure S1B, S1C). In addition, the morphological 
characterization of the vHMEC populations made it 
possible to determine whether the polyploid fraction of 
cells was made up of MN and/or BN cells (Figure 1B, 1C). 
Both types of polyploid populations increased with PDs in 
each vHMEC cell line without either being predominant 
(X2, p = 0.638 in 830; X2, p = 0.167 in 440212). Therefore, 
these results indicate that the intensification of the 
telomere-dysfunction phenotype in vHMECs engenders 
increasing polyploid populations that most likely arise 
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through both cytokinesis failure and bypass of mitosis and 
endoreduplication.
Centrosome aberrations increase -both in number 
and in size -in diploid and polyploid vHMECs
The emergence of polyploid populations throughout 
the cell culture would lead to the presence of cells with 
supernumerary centrosomes. Therefore, we assessed and 
quantified for the presence of centrosome aberrations in 
vHMEC. Immunofluorescence using antibodies specific 
for β-tubulin and pericentrin, a core component of the 
pericentriolar protein rich matrix (PCM), was performed 
throughout the cell culture. Centrosome numbers 
vary during the cell cycle: at G1, cells contain a single 
centrosome that duplicates once the cell enters S-phase; 
the duplicated centrosomes mature during G2; and at 
the onset of mitosis separate to form the bipolar spindle. 
Therefore, a cell containing more than two centrosomes, 
i.e. more than two pericentrin dots per cell, should be 
considered abnormal. The mean number of pericentrin 
signals per cell at early PD stages was 1.17 and this 
rate significantly increased to 1.45 in late PDs (U-Mann 
Whitney, p < 0.05). Even though cells carrying > 2CT 
significantly increased with PDs (0.4% on PD21 up to 
4.4% on PD34, X2, P < 0.05), they were few in number 
and seen mainly at late PD (Figure 2A, 2B). 
Given that telomere-dysfunction engenders 
Figure 1: Tetraploidization events are promoted by telomere-dysfunction. Variant human mammary epithelial cells (vHMECs) 
derived from distinct donors were analyzed for ploidy levels using β-tubulin antibodies in combination with oligonucleotide specific probes 
for the centromeric region of chromosome 6 and 12. A. vHMECs from donor 830 and 440212 were grown on chamber-slides at early 
and late PDs and processed with ImmunoFISH protocols. Tetraploidization events increase significantly with PDs in both, donor 830 
and 440212. *P < 0.05 X2-test. B. The combined detection of β-tubulin and centromeric specific DNA probes allowed the morphology of 
polyploid cells to be distinguished. Polyploid cells were either mononucleated (MN) or binucleated (BN) and both types of cells increased 
with PDs with no prominent differences between the two types. C. Representative image of vHMECs after ImmunoFISH protocols. The top 
image shows two mononucleated polyploid cells after mitosis still connected by a cytoplasmic bridge. Each nucleus displays four copies of 
each centromeric-specific probe. The bottom image shows a binucleated polyploid cell. White bar represents 10 μm. 
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Table 1: Size centrosome aberrations in diploid and polyploid vHMECs
Large CT
 2N >2N TOTAL
830vHMEC
Early 6.59% 2.93% 9.52%
Late PD 11.35% 13.83% 25.17%
440212vHMEC
Early 4.87% 2.67% 7.47%
Late PD 9.04% 16.22% 25.26%
Figure 2: Centrosome aberrations in vHMECs increase with PDs. A. The number of centrosomes per cell and throughout 
the PDs was analyzed using β-tubulin and the centrosome marker pericentrin. At early PD, vHMECs contained mostly one centrosome 
(1CT) or two centrosomes (2CT) per cell. vHMECs with more than 2 centrosomes ( > 2CT) are virtually recorded at late PD. Error bars, 
standard error of the mean; n = 2, *P < 0.05 X2-test (early PD vs. late PD). B. Representative micrographs of pericentrin and β-tubulin 
by immunofluorescence. Mononucleated cell with one pericentrin signal (upper left) and with three pericentrin signals (upper right) and a 
binucleated cell showing two pericentrin signals (bottom). Pericentrin signals are pointed with open arrows. DNA is counterstained with 
DAPI. Bar represents 10 μm. C. The use of immunoFISH protocols allowed for the accurate analysis of centrosome numbers in vHMECs 
according to their ploidy status. Abnormal centrosome numbers, more than 2CT, prevailed in polyploid vHMECs rather than in diploid. But 
strikingly, more than half of polyploid vHMECs at late PD contained only one pericentrin spot. Error bars, standard error of the mean; n = 
2. D. Representative images of vHMECs after immunoFISH of pericentrin antibodies and centromeric probes for chromosome 6 and 12. 
Mononucleated diploid cell with 2 CT (upper left), binucleated tetraploid cell with 2 CT (upper right), mononucleated tetraploid cell with 
4CT (bottom left), and mononucleated tetraploid cell with only 1 CT (bottom right). Pericentrin signals are pointed with open arrows and 
DNA is counterstained with DAPI. White bar on micrographs represents 5 μm. In this analysis, results of both cell lines were plotted as no 
statistical differences between them were observed. 
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polyploid cells, it was of relevance to ascertain whether 
mononucleated cells were diploid and contained a 
correct number of centrosomes, i.e. 1 or 2, or instead 
were polyploid and thus showed an aberrant number 
of centrosomes per cell. Therefore, we performed an 
immunoFISH protocol combining pericentrin antibodies 
with centromere-specific oligoFISH probes to evaluate 
centrosome aberrations in the diploid and polyploid 
fraction of cells (Figure S2). Throughout the cell culture 
most diploid cells displayed either 1 or 2 centrosomes; 
only 3 out of 472 diploid cells presented more than two 
centrosomes at late PD (Figure 2C, 2D). Notwithstanding, 
the most surprising observation was that more than half 
of the polyploid population of cells (69% at early PD and 
56% at late PD) presented only one centrosome (Figure 
2C, 2D). As polyploid cells should present at least 2 
CT, except in the case of clustering of centrosomes or 
extrusion of one centrosome outside the cell, centrosome 
size aberrations were also quantified in vHMECs. 
Abnormally large centrosomes, i.e. showing a 
pericentrin signal that was more than twice their usual size, 
were observed in vHMECs (Figure 3A). Significantly, 
these aberrantly sized centrosomes were observed both 
in diploid and polyploid vHMEC populations at a higher 
incidence than numerical centrosome aberrations (Table 
1). And their frequency significantly increased with 
PDs, both in diploid (6.59% up to 11.35% on 830, X2, 
p < 0.05; 4.87% up to 9.04% on 440212, X2, p < 0.05) 
and in polyploid vHMECs (2.93% up to 13.83% on 830, 
X2, p < 0.05; 2.67% up to 16.22% on 440212, X2, p < 
0.05) (Table 1). In order to determine if these abnormally 
large pericentrin signals corresponded to centriole 
amplification events rather than a normal centrosome 
matrix enlargement [24], immunofluorescence using 
antibodies against pericentrin and centrin, which label 
single centrioles, was performed in vHMEC-hTERT. 
After analyzing 114 centrosomes, it was found that a 
size increase in the pericentrin labeling area was directly 
related to an increase of centrioles per centrosome. The 
area of a pericentrin signal containing 2 or 4 centrioles 
had a mean size of 0.468±0.28 μm2, whereas centrosomes 
with more than 4 centrioles had a mean pericentrin area 
of 1.272±0.41 μm2 (ANOVA, P < 0.05) (Figure 3B, 3C). 
Therefore, these results support that an enlargement in the 
size of the pericentrin labeling area is directly related to a 
higher number of centrioles per centrosome. 
Overall, centrosome abnormalities significantly 
increased in vHMECs with PDs in parallel with the 
intensification of the telomere-dysfunction phenotype. 
These aberrations consisted of supernumerary, as well as 
oversized centrosomes. Importantly, large centrosomes, 
which were the predominant type of centrosome 
aberrations in vHMECs, could account for an excess 
number of centrioles per centrosome.
vHMECs acquire supernumerary centrioles 
throughout the cell culture
Considering that increased centrosome volume 
and supernumerary centrioles are observed in breast 
carcinogenesis [3, 25], we sought to confirm whether 
centriole amplification events occurred in p16INK4a-
deficient vHMECs. To do this, immunofluorescence 
using antibodies against centrin were combined with 
NEDD1 (neural precursor cell expressed developmentally 
downregulated gene 1), a protein component of the PCM 
Table 2: NEDD1/centrin staining in vHMECs
Early PD Late PD
830 440212 830 440212
n % n % n % n %
M
O
N
O
N
U
C
L
E
A
T
E
D
2 NEDD1/2 Centrin 767 67.52% 636 62.85% 111 36.04% 361 52.24%
2 NEDD1/4 Centrin 39 3.43% 240 23.72% 46 14.94% 96 13.89%
4 NEDD1/4 Centrin 230 20.25% 17 1.68% 71 23.05% 91 13.17%
SUBTOTAL 1036 91.20% 893 88.24% 228 74.03% 548 79.31%
2 NEDD1/> 4 Centrin 10 0.88% 61 6.03% 2 0.65% 47 6.80%
4 NEDD1/>4 Centrin 19 1.67% 12 1.19% 14 4.55% 25 3.62%
>4 NEDD1/>4 Centrin 36 3.17% 10 0.99% 17 5.52% 24 3.47%
SUBTOTAL 65 5.72% 83 8.20% 33 10.71% 96 13.89%
MN TOTAL 1101 96.92% 976 96.44% 261 84.74% 644 93.20%
B
IN
U
C
L
E
A
T
E
D 4 NEDD1/4 Centrin 28 2.46% 19 1.88% 37 12.01% 22 3.18%
SUBTOTAL 28 2.46% 19 1.88% 37 12.01% 22 3.18%
4 NEDD1/>4 Centrin 1 0.09% 14 1.38% 1 0.32% 11 1.59%
>4 NEDD1/>4 Centrin 6 0.53% 3 0.30% 9 2.92% 14 2.03%
SUBTOTAL 7 0.62% 17 1.68% 10 3.25% 25 3.62%
BN TOTAL 35 3.08% 36 3.56% 47 15.26% 47 6.80%
1136 1012 308 691
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that forms ring-shaped patterns around the mother and, to 
a lesser extent, the daughter centriole [26]. The analysis 
of 3147 cells, allowed identifying the most frequent 
NEDD1/centrin staining in MN and BN vHMECs (Table 
2 and Figure S3). Usually all NEDD1/centrin signals 
were morphologically in close association, but some 
fragmentation of the centrosome, where single co-stained 
dots of NEDD1/centrin were spread throughout the 
cytoplasm, was also observed (Figure 4A). Moreover, and 
in agreement with [21] centrosome splitting significantly 
increased with PDs (0.09% vs 3.75% on 830, X2, p < 0.05; 
0.20% vs 1.83% on 440212, X2, p < 0.05), albeit it was 
not the most frequent centrosome abnormality in vHMECs 
throughout the PDs. Centriole splitting in telomere-
compromised vHMEC usually affected all centriole 
pairs and was demonstrated by huge flat cells that were 
probably senescent. This fits in with other studies that 
have reported an increase in supernumerary centrosomes, 
most likely due to centrosome fragmentation, coincident 
with the entry of late passage MEFs into senescence [27].
Noteworthy, the main centrosomal aberration 
observed was the presence of centrin amplification 
events, i.e. more than 4 centrin signals per cell, which 
increased significantly with PDs (0.063 of cells at early 
PD to 0.140 at late PD on 830, X2, p < 0.05; and 0.099 
of cells at early PD to 0.175 at late PD on 440212, X2, p 
< 0.05) (Table 2 and Figures 4B, 4C). Intensification of 
centrin amplifications events also increased throughout the 
cell culture for both MN and BN vHMECs (X2, p < 0.05, 
for both cell lines; Table 2). Collectively, whereas the 
observation of amplification events in BN cells established 
that this phenomenon occurred in the tetraploid fraction of 
vHMECs, it was not clear whether centrin amplification 
events also occurred in the diploid fraction of cells, as MN 
cells with different ploidy content coexist throughout the 
vHMEC culture.
At that point, a direct assessment to establish 
whether MN vHMECs showing centrin amplification 
events were either diploid or tetraploid in nature was 
difficult to obtain as it was not feasible to combine centrin 
staining with in situ hybridization. However, immunoFISH 
analysis of NEDD1 combined with two DNA probes 
Figure 3: Large centrosomes, indicative of centriole amplification events, are observed in vHMECs. Immunofluorescence 
protocols demonstrated the presence of large centrosomes. A. The micrograph shows two mononucleated cells after pericentrin and 
β-tubulin staining. The cell on the right side displays—pointed arrow—a large pericentrin signal, bigger than twice the pericentrin signal of 
the upper left side cell. The bar represents 5 μm. B. The use of antibodies against pericentrin and centrin in vHMEC-hTERT determined that 
pericentrin area size became greater with an increasing number of centrioles. C. Pericentrin and centrin immunofluorescence, of three cells 
showing increasing numbers of centrin dots in green: 2 centrin signals (left side), 4 centrin signals (middle), and > 10 centrin signals (right 
side), and pericentrin area size in red. At the bottom of each image, insets showing individual centrin, pericentrin and merged respective 
images. Bar represents 5 μm.
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Figure 4: Amplification of centrioles occurs in mononucleated and binucleated vHMECs, and increases with PDs. 
A. Centriole splitting, where centrin dots co-stained with NEDD1 are dispersed throughout the cytoplasm, occurs in vHMECs. At least 8 
centrin/NEDD1 co-stained marks are observed in this cell, which consist of four centrin/NEDD1 singlets and two centrin/NEDD1 doublets. 
At the bottom of the image, insets show individual centrin, NEDD1 and merged image. Bar, 5 μm. B. Amplification of centrin—more than 
four spots—increases with PDs in both mononucleated and binucleated vHMECs. Error bars, standard error of the mean; n = 2, *P < 0.05 
X2-test (early PD vs. late PD). C. Representative images of amplification of centrioles. On the first row, mononucleated vHMECs with > 
4 centrin signals in combination with: 2 NEDD1 signals (left side), 4 NEDD1 signals (center) and > 4 NEDD1 signals (right side). On the 
second row, binucleated vHMECs with > 4 centrin signals in combination with: 4 NEDD1 (left side) or > 4 NEDD1 signals (right side). At 
the bottom of each image, insets show individual centrin and NEDD1 signals and the merged image. Bar, 5 μm. 
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demonstrated that MN cells showing 2 NEDD1 signals 
were diploid (47/47) whereas MN cells showing 4 
NEDD1 signals were either diploid (10/25) or polyploid 
(15/25) (Figure 5A, 5B). Of relevance, these observations, 
together with the NEDD1/centrin staining patterns (Figure 
S3), revealed that similarly to centrin, NEDD1 protein also 
duplicates during the cell cycle and does it slightly later. 
Moreover, it indicated that cells containing 2 NEDD1 
signals are truly diploid; cells with 4 NEDD1 signals are 
either diploid cells at late S/G2 cell cycle phase -2n2c DNA 
content- or tetraploid cells in G1/early S-phase -4nc DNA 
content-; and that cells containing > 4NEDD1 signals 
should be tetraploid cells at late S/G2 -4n2c DNA content- 
or octoploid cells in G1/early S-phase -8nc DNA content. 
As a whole, considering that amplification of centrioles is 
observed in cells containing 2 NEDD1, 4 NEDD1 and > 4 
NEDD1 signals (Table 2), these results support the view 
that amplification of centrioles occurs in both diploid and 
polyploid vHMECs. 
Another relevant question was to understand why, 
Figure 5: Cells showing 4 NEDD1 signals are either diploid or polyploid. ImmunoFISH protocol of NEDD1 (red) antibody 
and DNA specific probes CEP4 -aqua- and LSI22 -green- , were combined to determine the DNA content of mononucleated cells with 2 
and 4 NEDD1 signals. A. Representative images of diploid vHMECs with two (top side) and four (bottom side) NEDD1 signals. Scale bar 
represents 10 μm. B. Images show binucleated and mononucleated tetraploid vHMEC cells with 4 NEDD1 signals. Scale bar represents 
10 μm.
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among the fraction of cells with amplified centrioles, 
only MN cells showing 4 NEDD1 signals significantly 
increased with PDs despite that the intensification of 
centrin amplification events occurred throughout the 
cell culture for both MN and BN vHMECs (Table 2). 
It must be considered that cells with 4 NEDD1 signals 
are a mixture of diploid and tetraploid cells. So that 
when a given diploid cell with amplified centrosomes 
duplicates NEDD1 protein, it raises the frequency of 
MN cells harboring 4 NEDD1 signals. Then, if this cell 
divides properly, the increased number of centrioles will 
be distributed into the two resulting daughter cells, thus 
diluting the amplified phenotype in the diploid with 2 
NEDD1 signals fraction of cells. In contrast, if division 
does not occur, amplification events will accumulate with 
PDs in the tetraploid with 4 NEDD1 signals fraction of 
cells, giving their low mitotic index.
Both centriole accumulation and overduplication 
account for extremely large centrosomes
To get further insight into the process responsible 
for centriole aberrations in vHMECs, it was important 
to establish whether centriole amplification emerged 
from a deregulation of the centriole replication cycle, i.e. 
centriole overduplication, or through accumulation of 
centrioles due to tetraploidization events. For that reason, 
we took advantage of the CEP170 antibody, a protein that 
localizes to the mother centriole sub-distal appendages 
[28] in combination with centrin. Using these antibodies, 
genuine centriole overduplication can be distinguished 
from centriole accumulation using the ratio between 
immature and mature centrioles (Figure S4).
Quantification of CEP170/centrin staining in 440212 
vHMEC cell line demonstrated that both accumulation and 
overduplication of centrioles were taking place throughout 
the cell culture (Figure 6A). Centriole overduplication 
affected mainly MN vHMECs and their incidence 
increased significantly with PDs (9.99% at early PD vs 
17.86% at late PD, X2, p < 0.05). BN cells with centriole 
overduplication were few and no statistical increase was 
observed throughout the cell culture (X2, p = 0.702) 
(Figure 6A, 6B). Accumulation of centrioles affected both 
MN and BN cells, and intensification of this event was 
observed throughout the PDs (4.85% vs 10.88% for MN 
and 2.95% vs 6.66% for BN, X2, p < 0.05 for both types of 
cells). These results support the view that, in vHMECs, the 
emergence of polyploid cells throughout the cell culture 
leads to the accumulation of centrosomes with PDs. 
However, the presence of centriole overduplication events 
in MN cells suggests that other processes apart from 
tetraploidization might instigate centrosome abnormalities 
in vHMECs. In this regard, it has been determined that the 
suppressed expression of p16INK4a in different cell types is 
coupled to centrosome dysfunction [21]. To corroborate 
this, we tested whether p16INK4a-proficient pre-stasis 
HMECs isolated from mammary tissue did present a 
centrosome-deficient phenotype. Centriole aberrations 
were evaluated after CEP170/centrin staining in pre-
stasis HMECs at PD3 and compared to the incidence 
observed in p16INK4a-deficient 440212 vHMECs at early 
PD (PD21). Notably, a significant increase in centriole 
overduplication was observed in those cells where p16INK4a 
was compromised (10.1% vs 2.4%, in post-stasis 440212 
vHMEC and pre-stasis HMEC, respectively; X2, p < 0.05). 
Therefore, these data further confirm that loss of p16INK4a 
in HMECs plays a causal role in centrosome dysfunction. 
Centrosome abnormalities decrease over time 
when telomere damage is abolished
To delineate p16INK4a deficiency as the only factor 
responsible for the generation of centrosome aberrations, 
vHMECs were immortalized with hTERT to minimize 
the telomere-dysfunction phenotype. vHMECs were 
transduced at early PD and their immediate and long 
effects on ploidy status and centrosome numbers and 
size were assessed. The restoration of telomerase 
function stabilizes the chromosome ends and thus might 
attenuate the generation of tetraploid cells. Accordingly, 
both vHMEC-hTERT cell lines showed telomeric FISH 
signals at the tips of all chromosomes and there was no 
evidence of telomere-dependent instability in the form of 
dicentric chromosomes at long times post-transduction 
(Figure S1B). Moreover, the analysis of cell ploidy 
with oligoFISH probes in vHMEC-hTERT grown in 
chamberslides showed a significant reduction of polyploid 
cells with increasing PDs, from 15.08% at PD35 to 4.04% 
at PD180 in 440212-hTERT, X2, p < 0.05, (Figure 7A) and 
from 10.83% at PD35 to 0.58% at PD132 in 830-hTERT, 
X2, p < 0.05 (Figure not shown). Particularly, in 440212 
transduced cells, a slight increase was observed in the 
fraction of polyploidy cells 15 PDs after infection, thus 
indicating that once telomerase function is restored, there 
is a lag time before chromosome ends become capped 
(Figure 7A). 
It was then assessed whether reactivation of 
telomerase and reduction of telomere-dependent damage 
lead in turn to a significant reduction of centrosome 
abnormalities in the transduced vHMEC-hTERT 
throughout the culture. Pericentrin staining in 440212 
immortalized vHMEC depicted a reduction of centrosome 
aberrations, in number and in size, with PDs following 
telomerase reactivation and after an initial lag phase 
(Figure 7B). Importantly, when centrosome aberrations 
were distributed according to cell ploidy status, it was 
determined that the polyploid fraction of cells with 
centrosome aberrations decreased significantly at PD85 
(X2, p < 0.05) (Figure 7C), concomitant with the reduction 
of polyploid cells most probably due to the impossibility 
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Figure 6: Centriole overduplication and accumulation increase in vHMEC with PDs. By double staining of centrin 
antibodies—green—which labels all centrioles, and CEP170 antibodies—red—which labels mother centrioles, it was possible to evaluate 
the possible mechanisms accounting for centriole amplification events. A. Overduplication of centrioles was mainly seen in mononucleated 
-MN- vHMECs. In contrast, accumulation of centrioles was observed in both MN and binucleated -BN- vHMECs. * P < 0.05 X2-test, 
(early PD vs. late PD). B. Representative images of centriole overduplication: > 4 centrin signals together with 1 or 2 CEP170 spots. The 
MN cell—on the left side—displays 8 centrin signals and two CEP170. The BN vHMEC—on the right side—displays at least 8 centrin 
signals and 2 CEP170 spots. At the bottom of each image, insets show individual centrin and CEP170 signals and the merged image. C. 
Representative images of centrosome accumulation events. In MN cells, accumulation of centrosomes was considered when the cells 
displayed > 4 centrin signals and at least 50% of them were CEP170 labeled. This is the case for the vHMEC on the left side, showing 7 
centrin signals. In BN cells, accumulation of centrosomes was considered when 4 centrin signals together with 2 CEP170 were recorded. 
An example of a BN vHMEC with accumulation of centrosomes is observed on the right side. At the bottom of each image, insets show 
individual centrin and CEP170 signals and the merged image. Bar represents 5 μm. 
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of overcoming the p53 activation triggered by tetraploidy 
[29]. In contrast, attenuation of centrosome abnormalities 
in the diploid fraction of cells smoothed gradually over 
PDs (Figure 7C). Although it was not feasible to co-
stain the cells for centrosome and senescent/apoptotic 
markers, there appeared to be a selection against diploid 
cells showing centrosome abnormalities. Notably, it has 
been described that centrosome amplification leads to an 
elevation of p53 levels and a corresponding decrease in 
proliferation of non-transformed cells [30]. Altogether, 
these data indicate a cooperative interaction of p16INK4a-
deficiency and telomere-dependent DNA damage in the 
generation of centrosome aberrations in vHMECs.
To further confirm this connection, DNA-damage 
was induced in the p16INK4a-deficient vHMEC-hTERT by 
exposing the cells to ionizing radiation. vHMEC-hTERT at 
PD170 were irradiated under a cesium device and 48 hours 
later centrosome damage was evaluated. Genotoxic stress, 
in the form of DSBs, once again increased centrosome 
aberrations in vHMEC-hTERT (3.7% vs 9.5%, X2, p < 
0.05) (Figure 7D), confirming the presence of anomalies 
in both number and size. In addition, CEP170/centrin 
immunofluorescence showed a significant increase in 
both overduplication (1.6% vs 5.3%, X2, p < 0.05) and 
accumulation of centrioles (1.1% vs 3.3%, X2, p < 0.05) 
in the irradiated cells. A somewhat higher proportion of 
cells with > 2CT was observed after radiation-induced 
genotoxic stress than after extensive telomere dysfunction 
(20% in irradiated vHMEC-hTERT vs 12.2% in post-stasis 
vHMEC at late PD, X2, p < 0.065), which could represent 
the premature disengagement and licensing effect of 
ionizing radiation [31]. Nevertheless, the induction of 
DNA damage in p16INK4a-deficient vHMEC-hTERT cells 
concluded again in a significant increase in centriole 
amplification events. 
Figure 7: Restoration of telomere length reduces centrosome aberrations both in diploid and polyploid vHMECs-
hTERT Immortalization of vHMECs was accomplished at early PD by transducing the cells with hTERT. A. Evolution 
of polyploidization events in mortal cells - vHMECs - and immortal cells - vHMEC-hTERT - throughout the PDs. Transduction of vHMECs 
with hTERT concluded with the reduction of the polyploid fraction of cells because of suppression of the telomere-dysfunction phenotype 
and their compromised viability. B. Centrosome aberrations were followed during culture expansion of vHMEC and vHMEC-hTERT 
by means of β-tubulin and pericentrin immunofluorescence. Note that centrosome aberrations decline over PDs when chromosome ends 
are capped. C. ImmunoFISH protocols allowed a decline of centrosome aberrations to be determined in diploid and polyploid vHMEC-
hTERT. D. DNA damage in the form of telomere-dysfunction increased centrosome aberrations in p16INK4a-deficient vHMECs. Telomerase 
reactivation and capping of telomere DNA free ends resulted in a progressive reduction of centrosome aberrations. The induction of DSBs 
in vHMEC-hTERT, through exposure to ionizing radiation, increased the centrosome aberrations again in vHMECs. 
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Telomere-dependent instability activates the DNA 
damage checkpoint in proliferating vHMECs
A transient inhibition of DNA synthesis has been 
documented to be required for p16INK4a-deficient cells to 
generate more than two centrosomes in a Cdk2-dependent 
manner [21]. These authors demonstrated that in the 
absence of a functional p16INK4a and upon hydroxyurea-
induced DNA damage, p21WAF1/CIP1 cannot disengage 
from the cyclin D1/Cdk4/p21WAF1/CIP1 complex and thus 
completely inactivate cyclin E/A-Cdk2 [21]. Given that 
vHMECs proliferation is associated with the accumulation 
of uncapped telomeres, as well as the presence of double 
strand breaks [32], it is feasible that intrinsic DNA damage 
results in the activation of the DNA damage response 
(DDR), thus providing the opportunity for centrosome 
overduplication.
Figure 8: vHMECs accumulate DNA damage with PDs and slowdown DNA replication. A. Western blot analysis of protein 
extracts from control and treated vHMEC and vHMEC-hTERT cells. vHMEC and vHMEC-hTERT cells were exposed to 5Gy of gamma 
rays and processed 10 hours post-irradiation. vHMECs treated with 4 mM HU during 6 hours were used as positive control for collapsed 
replication forks. GAP120 was used as loading control. B. Cell cycle analysis of vHMEC cells at different PDs, as well as irradiated 
vHMECs and vHMECs-hTERT, was performed by measuring BrdU-Alexa488 levels and propidium iodide staining. BrdU-Alexa488 
positive cells are colored in purple, dark green represents cells with 2N DNA content, pale green represents 4N DNA content cells, and the 
yellow dots are cells with 8N DNA content. Legend (upper right) shows the distribution of cells with different DNA content. C. Histograms 
showing intensity levels of BrdU-Alexa488 positive vHMECs throughout PDs as well as irradiated vHMECs. Dashed line indicates the 
cut-off for BrdU positive cells.
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To test this, western blot analyses were conducted 
in 440212 vHMECs to examine the expression of proteins 
associated with genotoxic damage throughout the cell 
culture. These experiments confirmed the results of 
previous studies, showing expression of wild-type p53 
and p21 in cells lacking p16INK4a expression [33-35]. No 
Chk1 or RPA-32 phosphorylation were observed in finite 
vHMEC, or in early or late PDs, indicating that there were 
not stalled or collapsed replication forks in these cells 
(Figure 8A). In contrast, phosphorylation of Chk2 and 
expression of p53 and p21WAF1/CIP1 were shown to increase 
with PDs in finite vHMEC (Figure 8A). Furthermore, 
irradiation of these cells induced only a slight increase in 
Chk2 phosphorylation that did not result in an increment 
in p53 and p21WAF1/CIP1 protein levels. Collectively, 
activation of Chk2-p53-p21 pathway throughout the cell 
culture indicates the accumulation of DNA damage in 
proliferating vHMECs. Next, we investigated whether 
vHMEC-hTERT also exhibit elevated levels of DDR 
proteins. Considering that telomere-dependent damage is 
abolished through telomerase expression, we expected a 
reduction of endogenous genotoxic damage and absence 
of DDR activation in hTERT stably expressing cells. 
Indeed, Chk2 phosphorylation on Thr68 was negligible 
in immortalized vHMECs. Moreover, although these cells 
have higher basal p21WAF1/CIP1 and p53 expression, upon 
irradiation they show Chk2 phosphorylation and a further 
increase in p53 and p21WAF1/CIP1 levels. In addition, no Chk1 
or RPA-32 phosphorylation was observed unless HU was 
added (Figure 8A). Therefore, these data strongly support 
that proliferating vHMECs activate the Chk2-p53-p21 
cascade with increasing PDs due to the accumulation of 
DSBs, probably arising from telomere uncapping.
We then aimed to assess whether finite vHMEC cells 
in late PDs also showed cell cycle arrest in association 
with the DDR activation. Cell cycle progression was 
monitored by FACS following a 30 minutes pulse with 
BrdU and propidium iodide staining. Proliferation of 
finite vHMECs resulted in a marked reduction of G1 cells 
(68.8% vs 44.4%, 2N fraction in the cytometer) and an 
increase of G2/M cells (21.6% vs 43.3%, 4N fraction 
in the cytometer) with PDs (Figure 8B). These results 
suggest that, similarly to irradiation, endogenous DNA 
damage observed in late vHMECs leads to the activation 
of the G2/M-checkpoint. However, the rise in the 8N 
fraction of cells at late PDs, and the already reported 
accumulation of cyclin D1 positive tetraploid vHMECs 
in the 4N DNA content window [9], did not allow to 
unambiguously determine the percentage of diploid cells 
corresponding to G2/M arrested cells. Nevertheless, the 
shift in BrdU intensity of late PD cells compared to early 
PD ones may indicate a slowdown in replication in late 
PD cells in response to telomere-dependent DNA damage. 
Consistent with this, a similar shift of BrdU incorporation 
was obtained in vHMECs after IR-induced genotoxic 
stress (Figure 8C). Taken together, all these data indicate 
that vHMECs cells accumulate DNA damage with PDs, in 
correlation with a delay in cell cycle progression in the S 
and G2/M phases.
DISCUSSION
Almost all breast tumors (80-100%) display 
centrosome amplification [36]. In breast carcinogenesis, 
there is a significant correlation between centrosome 
aberrations and advancing disease [4]. Indeed, 
adenocarcinoma cells present abnormal numbers of 
centrosomes per cell; oversized centrosomes and/or 
centriole amplification, which are also observed to a 
lesser extent in pre-invasive in situ ductal carcinoma cells 
and/or pre-malignant breast lesions, thus revealing their 
premature onset in breast carcinogenesis [14, 36, 37]. 
Attempts to uncover the underlying origin of centrosome 
abnormalities in mammary carcinogenesis have 
determined a positive correlation between centrosome 
size and number defects with aneuploidy and CIN that is 
independent of p53 inactivation [14-16].
But how can centrosome defects arise early in 
breast carcinogenesis independently of p53 deficiencies? 
One possibility could be through targeting the pRB/
p16INK4a axis, an important pathway that modulates 
the proliferative lifespan of epithelial cells at the G1 
boundaries and regulates the timely expression of a 
plethora of genes involved in centrosome homeostasis. 
Disruption of the pRB/p16INK4a-pathway occurs commonly 
in breast cancer. Loss of heterozygosity at the RB gene 
locus has been determined to be around 20-30% [38, 
39] and overexpression or amplification of the cyclin 
D1 gene is observed in as many as 50% of cases [40]. 
Yet another mode of inactivation, with a prevalence 
ranging from 4% to 68.4%, is through CDKN2A promoter 
methylation [41-43]. This feature has been observed in 
various intraductal proliferative lesions as well as in high 
grade intraductal carcinomas [42]. Moreover, CDKN2A 
promoter methylation has been associated with a 6.58-fold 
increase of breast cancer risk [44] and occurs frequently 
in mammary cells obtained from women with greater 
chances of developing breast cancer [45, 46]. To unravel 
the importance of p16INK4a in the generation of centrosome 
amplification early in breast cancer development, we made 
use of p16INK4a proficient (pre-stasis HMEC) and deficient 
(vHMEC) human mammary epithelial cells. Our data 
provide evidence that p16INK4a-deficent vHMECs acquire 
increased numbers of centrosomes as well as centrosomes 
of greatly increased size that contain excessive numbers 
of centrioles concomitant to the accretion of telomere-
dependent instability. 
There is some controversy over the involvement 
of the pRB/p16INK4a pathway in the origin of centrosome 
amplification. Leading studies have relied on the cell-cycle 
deregulation potential of human papilloma virus (HPV16) 
oncoproteins. The E7 oncoprotein has specifically been 
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shown to induce prompt abnormal centrosome synthesis 
-seen as increased procentriole formation through electron 
microscope analysis -before the development of extensive 
nuclear abnormalities [47, 48] and polyploidization events 
[49]. HPV16 E7-expressing cells show a prolonged 
S-arrest, where an increased formation of immature 
daughter centrioles is produced [28] by a process similar 
to the one operating in hydroxyurea-treated cells [50]. 
Indeed, concurrent formation of more than one daughter 
centriole in single maternal templates, i.e. a rosette-like 
pattern, within a single S-phase, has been observed in 
cells expressing HPV16 E7 [51]. Nevertheless, any role 
of E7 oncoprotein in centrosome amplification must 
take into account the overwhelming targets with which 
this oncoprotein interacts, as it binds and degrades pRb, 
inactivates p21 and deregulates the expression of cyclin 
E, among others. In an attempt to better clarify this 
question, ectopic Cdk4 overexpression has been induced 
in immortalized keratinocytes (NOK-hTERT), given 
that it interferes with the inhibitory effect of p16INK4a and 
results in increased pRB phosphorylation levels [52]. In 
that study, in striking contrast to what was observed in 
NOK-hTERT transduced with HPV16 E7, overexpression 
of Cdk4 in NOK-hTERT did not alter the centrosome 
duplication cycle [52], thus reflecting that abrogation 
of the pRb/p16INK4a checkpoint does not necessarily 
lead to centrosome abnormalities. Furthermore, and in 
accordance with these observations, downregulation of 
p16INK4a protein expression using specific shRNA in pre-
stasis HMECs only resulted in a significant increase in 
centrosome amplification when cells were treated with 
hydroxyurea, an inhibitor of ribonucleotide reductase 
activity that induces replication stress DNA damage 
[21]. In the study concerned, centriole pair splitting was 
determined to be the main cause of centrosome aberrations 
in p16INK4a-deficient cells [21]. In addition, the same was 
found to occur in human mammary and newborn dermal 
foreskin fibroblasts transduced with p16INK4a shRNA when 
exposed to hydroxyurea [21]. As a whole, all these studies 
support the notion that p16INK4a prevents centrosome 
dysfunction when DNA damage is inflicted. 
Given that telomere dysfunction is able to trigger 
a DNA damage response, it has been speculated that 
telomeric erosion may affect the status of the centrosome 
and even affect its amplification under the influence 
of DNA damage signaling [53]. In pre-stasis HMECs, 
inactivation of p16INK4a allows cells to bypass senescence 
and display proliferative-dependent telomere dysfunction 
that ends up in uncapped chromosomes [20, 32]. 
Moreover, during proliferation, p16INK4a-deficient vHMECs 
accumulate uncapped DNA ends, as well as proper DSBs 
resulting from the entrance of end-to-end fusions into 
BFB-cycles [32]. Therefore, it could be considered that 
telomere-driven endogenous genotoxic stress could well 
be responsible for the centrosome amplification signature 
seen in telomere-compromised p16INK4a-deficent vHMECs. 
Indeed, our results illustrate that centrosome amplification 
events increased in parallel with intensification of DNA 
damage, probably arising from telomere uncapping, and 
restoration of telomere length by hTERT transduction 
concluded in the attenuation of the aberrant centrosome 
phenotype in diploid and polyploid cells. In agreement 
with these observations, disruption of the telomeric t-loop, 
through siRNA of the shelterin proteins TRF1 or POT1, 
in p16INK4a-deficient U2OS cell line, also resulted in an 
increase in supernumerary centrosomes [53].
Of even greater interest, we observed that alternative 
routes for centrosome amplification exist in telomere-
compromised p16INK4a-deficient vHMEC. Whereas 
telomere-dependent polyploidization events ended up 
in abnormal centrosome numbers per cell -centrosome 
accumulation -telomere dysfunction also resulted in 
enlarged centrosomes that contained excessive numbers 
of centrioles -indicative that centrosome overduplication 
events were taking place. Centrosome duplication, like 
chromosome duplication, is initiated by Cdk2 [50], and 
similar to chromosomal DNA, centrosomes possess 
an intrinsic mechanism that ordinarily prevents their 
reduplication within a single cell cycle [54]. However, the 
coupling between centrosome duplication and cell cycle 
progression is much less robust with respect to conditions 
that impair cell cycle progression, and this condition is 
exacerbated when DNA damage is inflicted in cells with 
cell cycle checkpoint deficiencies. Indeed, mammalian 
cells lacking proper checkpoints controls are able to 
reduplicate their centrioles upon transient S-phase arrest, 
likely due to increased cyclin E-Cdk2 activity [reviewed 
by 55]. Similarly, when vHMECs are exposed to HU, 
which triggers inhibition of the DNA replication cycle, 
the absence of p16INK4a allows the duplicated centrosomes 
to progress into a second round of centrosome duplication 
due to unregulated Cdk2 activity [21]. According to this 
model, the kinase activity of the cyclin E/A-Cdk2 is not 
completely inhibited by the CDKI p21WAF1/CIP1 because, 
in the absence of p16INK4a protein, it remains associated 
with the cyclin D1-Cdk4 complex [21]. Our results in 
telomere-compromised vHMECs fit well with this model 
as accumulation of uncapped telomeres and DSBs with 
PDs results in the activation of the Chk2-p53-p21 cascade 
and a delay in cell cycle progression that could end up in 
the centrin amplification events observed. Nevertheless, 
the model depicted by McDermott does not resolve what 
occurs when p21WAF1/CIP1 levels rise due to DDR activation. 
Yet another possible explanation for cyclin E-Cdk2 
upregulation comes from studies using a mutant CDK2 that 
lacks inhibitory phosphorylation sites [56]. Experiments 
showed that mutant MEFs with elevated Cdk2 activity 
had elevated numbers of centrosomes compared to wild-
type MEFs, and this phenotype increased extensively 
after UV-irradiation [56]. Importantly, the observance 
that centrosome numbers were essentially unaffected by 
knocking down p21WAF1/CIP1, led the authors conclude that 
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the subpopulation of cyclin E-Cdk2 that participates in 
centrosome duplication is located at the centrosome, so 
that it is physically separated from the nuclear protein 
p21WAF1/CIP1 [56]. As a whole, uncoupling of chromosome 
and centrosome duplication cycles occurs especially after 
checkpoint-induced cell cycle arrest, likely because cyclin 
A-Cdk2 activation would be further delayed relative to 
cyclin E-Cdk2 [56].
Although further studies are warranted to explore 
precisely the molecular pathways through which 
disruption of the pRB/p16INK4a axis leads to centriole 
amplification in the presence of telomere-dependent 
genotoxic stress, our work has uncovered a mechanistic 
link for the coincident detection of telomere erosion and 
centrosome aberrations early in cancer development, 
before TP53 mutations are gained. In addition, it supports 
the notion that unrestricted growth due to pRB/p16INK4a 
deficiencies, which occur in early breast lesions, will 
engender concomitant telomere- and centrosome-driven 
chromosome instability that, accompanied by other 
permissive lapses in cell cycle checkpoints, may underpin 
the onset of mammary carcinogenesis.
MATERIALS AND METHODS
Cells, culture and treatments
Post-stasis variant human mammary epithelial 
cells (vHMECs) 830 and 440212 were obtained from 
Cell Applications Inc. (San Diego, CA, USA). Pre-stasis 
HMEC were established from reduction mammoplasty 
tissue in accordance with previously reported methods 
[57]. The patient signed a written consent form allowing 
their tissue to be used for biological research; this consent 
was obtained by the medical staff at the hospital prior 
to surgery. All work with human derived material was 
reviewed and approved by the Human Subjects Protection 
Committee of the Universitat Autònoma de Barcelona. 
HMECs and vHMECs were cultured with serum-
free MEpiCM medium supplemented with MEpiCGS 
and penicillin/streptomycin (all from ScienCell Research 
Laboratories, Carlsbad, CA, USA). Growth conditions 
were 5% CO2 and 37
0C. Culture population doublings 
(PDs) were calculated using the formula: PD = PDinitial + 
log2 (Nfinal/Ninitial), where Ninitial is the number of viable cells 
plated, and N
final
 is the number of viable cells harvested. 
vHMECs are finite, and the ones used in this study had a 
proliferative potential of 35-38 PDs.
vHMECs expressing hTERT (vHMEC-hTERT) 
were generated by lentiviral transduction of 830 and 
440212 vHMECs at PD21, following standard procedures. 
The hTERT lentivirus was purchased from the Viral Vector 
Facility of CNIC (Spain). 
To induce binucleated cells and centriole 
accumulation, vHMECs-hTERT were treated for 24 hours 
with 6μg/ml cytochalasin B (Cyt-B, Sigma-Aldrich, Tres 
Cantos, Spain); centriole overduplication was induced in 
vHMECs-hTERT after treatment with 2mM hydroxyurea 
(HU, Sigma-Aldrich) for 48h. Generation of double strand 
breaks (DSB) was achieved by irradiating vHMEC-hTERT 
with 5Gy of γ-rays using an IBL-437C R-137Cs source. 
Antibodies
Primary antibodies used were mouse β-tubulin 
(1:1000, Sigma-Aldrich), rabbit pericentrin (1:2000, 
Abcam, Cambridge, UK), mouse pericentrin (1:2000, 
Abcam), rabbit centrin (1:2000, gift from R. Ohi), mouse 
CEP170 (1:2000, Life Technologies, Alcobendas, Madrid), 
and mouse NEDD1 (1:1000, Abnova, Taipei, Taiwan) 
and mouse BrdU (1:100, Santa Cruz Biotechnology, 
Heidelberg, Germany) for flow cytometric analysis. 
Secondary antibodies were anti-mouse Cy3 (1:1000, 
Amersham, GE Healthcare Europe GmbH, Barcelona, 
Spain), anti-rabbit Alexa 488, and anti-rabbit Alexa 568 
(both at 1:500, Life Technologies). 
Western blotting
Proteins were extracted with CHAPS lysis buffer 
and centrifuged at 40C with 20000 rcf. Protein extracts 
were quantified with NanoDrop 2000 (Thermo Fisher 
Scientific S.L., Barcelona, Spain) and denatured for 10 
minutes at 700C. The proteins were then separated using a 
10% SDS-PAGE gel (Life Technologies), and transferred 
to a nitrocellulose membrane. Antibodies used were, 
mouse p16INK4a (1:1000, Neomarkers, Fremont, CA, 
USA), mouse p53 (1:1000, Santa Cruz Biotechnologies, 
Heidelberg, GE) and mouse GAPDH (1:1000, Abcam) 
diluted in 1xPBS-3%BSA-0.1%Tween20. Horseradish 
peroxidase (HRP)-conjugate anti-mouse was used as 
secondary antibody (1:2000, Millipore, Madrid, Spain). 
Chemiluminescent detection of antibodies was performed 
using HRP solution and luminol (Immobilion Western kit, 
Millipore).
For P-Chk1 (S296), P-Chk2 (T68), p53, p21 and 
RPA32 protein detection (Figure 8), previously treated 
samples were collected in 2% SDS containing 67 mM 
Tris-HCl (pH 6.8) buffer. Protein extracts were denatured 
for 15 minutes at 95 ºC and quantified by common 
methods. The proteins were then run in Laemmli SDS-
polyacrylamide gels and transferred to nitrocellulose 
membranes before their detection with the indicated 
antibodies: rabbit P-Chk1 S296 (1:1000, Cell signaling, 
#2349), rabbit P-Chk2 T68 (1:1000, NB100-92502), 
mouse p53 (1:1000, Ab-5, MS-186), mouse p21 (1:1000, 
Ab-1, OP64), rat RPA32 (1:1000, Cell signaling, #2208) 
and mouse GAP120 (1:400, santa cruz, sc-63), diluted in 
1xPBS-3%BSA-0.05%Tween20. Horseradish peroxidase 
Oncotarget28253www.impactjournals.com/oncotarget
(HRP)-conjugate antibodies were used as secondary 
antibodies. Proteins were finally visualized using ECL 
detection system (Biological Industries).
Immunofluorescence
Cells plated onto chamber slides were fixed with ice-
cold methanol for 3 minutes when 70%-80% confluence 
was reached. The cells were then permeabilized with 
1xPBS-1%Triton-X-100 solution for 15 minutes and 
blocked with 1xPBS-0.1%Tween20-2% Fetal Calf Serum 
or 1xPBS-5%BSA for 1 hour at 370C. When centrin 
antibodies were specifically used, cells were incubated in 
KCM buffer (120mM KCl, 20mM NaCl, 10mM Tris-HCl 
-pH 8-, 0.5mM EDTA and 0.1% Triton X-100) prior to the 
permeabilization step. Incubation with primary antibodies 
diluted in blocking solution was performed for 1 hour at 
370C, and secondary antibodies were incubated for 30 
minutes in blocking solution at room temperature. When 
centrin antibodies were used, washes between different 
steps were in 1xPBS or PHEM buffer (60mM PIPES, 
25mM HEPES, 20mM EGTA, 2mM MgCl2). Finally, after 
secondary antibody incubation, samples were washed with 
1xPBS-0.5%Tween20, dehydrated and counterstained 
with 4’,6-diamidino-2-phenylindole (DAPI).
ImmunoFISH
ImmunoFISH protocol consists of performing 
immunofluorescence first, as described in the previous 
section, except for the final steps. After washing for 
excess secondary antibody with 1xPBS-0.5%Tween20 
the samples were fixed again using a microtubule 
stabilization and extraction fixative buffer (MTSB-XF; 
100mM PIPES, 5mM MgCl2, 2.5mM EGTA, 1mM DTT, 
1μM taxol, 0.01%, aprotinin, 50% deuterium oxide, 3.7% 
formaldehyde, 0.1% Triton X-100) for 5 minutes at 370C 
and fixed with 4% formaldehyde and then dehydrated. 
DNA denaturation was then achieved in 2xSSC-70% 
formamide for 10 minutes at 730C and followed by cold 
ethanol dehydration. For Pericentrin/oligoFISH analysis, 
the centromere of chromosome 6 (Gold DY539) and 12 
(Red DY590) oligonucleotide specific probes (OligoFISH 
Probes, Cellay Inc., Cambridge, MA, USA) were 
hybridized with the denatured samples overnight at 370C. 
Afterwards, the samples were briefly washed in 0.2xSSC-
0.1%SDS at 500C. For the NEDD1/FISH analysis, CEP 
4 and LSI 22 (bcr) DNA probes (Abbot, Abbot Park, IL) 
were denatured for 5 minutes at 740C and afterwards 
hybridized with the denatured samples at 370C overnight. 
Afterwards, the samples were washed with 0.4xSSC at 
73ºC for 1 minute and 2xSSC 0.5%Tween20 at room 
temperature for 1 minute. All slides were counterstained 
with DAPI after dehydration in graded series of alcohol.
Microscope analysis and size measurement
Fluorescence was evaluated under an optical 
epifluorescence microscope with specific filters for each of 
the used fluorochromes, and images were obtained using 
Isis Fluorescence Imaging software (MetaSystems GmbH, 
Altlussheim, DE), or Genus software (Cytovision, Leica 
Microsystems S.L.U., Barcelona, Spain).
Centrosome size measurement was performed in 
vHMEC-hTERT using antibodies against pericentrin, 
which label the pericentriolar material, and centrin, to 
visualize individual centrioles. The raw images of each 
single fluorochrome capture were processed with the Fiji 
package (http://fiji.sc/Fiji) [58], using a ROI management 
tool. 
Flow cytometric analysis
For tracking S phase cells, a pulse of 10μM BrdU 
was carried out for 30 minutes. Afterwards, cells were 
rinsed, trypsinized, centrifuged and fixed with 70% 
ethanol. The samples were kept at -200C until processing. 
Detection of BrdU incorporation was achieved following 
standard procedures after DNA denaturation with HCl 
2N-0.5%Triton-X-100. Before antibody detection, 
every sample was divided into two different tubes. 
One of the tubes was incubated with both anti-BrdU 
primary antibody and anti-mouse Alexa 488, the control 
tub was only incubated with the secondary antibody. 
Before acquiring the samples, they were counterstained 
with 0.5% Propidium Iodide (PI; 1mg/ml) in 1xPBS-
0.1%TritonX100 containing 0.2 mg/ml RNAase A 
DNAase-free (Sigma-Aldrich). Cell-cycle analysis was 
performed in a FACSCalibur. All results were analyzed 
with the BDFacsDiva software (BD Biosciences).
Statistical analysis
Data analysis was carried out with the statistical 
program SPSS 15.0 for Windows (SPSS Inc, University 
of Chicago). Statistical differences between the samples 
analyzed were considered to be significant when a p-value 
< 0.05 was obtained. 
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